Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Merck KGaA Pays Vertex $230M for Clinical and Preclinical Anticancer Programs

Vertex has licensed global development and commercialization rights to two clinical and two preclinical anticancer programs to Merck KGaA ...

Forward this item to a colleague:


(Separate multiple addresses by commas)